Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Given Average Rating of “Hold” by Analysts

Shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) have been assigned an average rating of “Hold” from the five brokerages that are presently covering the stock, MarketBeat reports. Four analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $3.33.

Separately, StockNews.com started coverage on Syros Pharmaceuticals in a research note on Thursday, March 13th. They issued a “sell” rating on the stock.

Institutional Trading of Syros Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. GSA Capital Partners LLP bought a new position in Syros Pharmaceuticals during the 3rd quarter valued at approximately $34,000. Two Sigma Securities LLC purchased a new position in shares of Syros Pharmaceuticals during the fourth quarter valued at approximately $25,000. Finally, Exome Asset Management LLC raised its holdings in shares of Syros Pharmaceuticals by 87.6% during the third quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock valued at $642,000 after acquiring an additional 139,400 shares in the last quarter. 91.47% of the stock is currently owned by hedge funds and other institutional investors.

Syros Pharmaceuticals Trading Down 7.1 %

SYRS opened at $0.09 on Tuesday. Syros Pharmaceuticals has a 12 month low of $0.07 and a 12 month high of $6.93. The business’s 50-day moving average price is $0.17 and its 200-day moving average price is $0.89. The company has a market cap of $2.30 million, a P/E ratio of -0.03 and a beta of 1.31.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.